Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Shares Traded Last Trade
  -12.00 -0.19% 6,390.00 1,748,232 16:35:17
Bid Price Offer Price High Price Low Price Open Price
6,376.00 6,379.00 6,454.00 6,359.00 6,420.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 17,322.09 1,562.83 133.31 47.0 83,823
Last Trade Time Trade Type Trade Size Trade Price Currency
17:52:07 O 2,206 6,390.00 GBX

Astrazeneca (AZN) Latest News

More Astrazeneca News
Astrazeneca Takeover Rumours

Astrazeneca (AZN) Share Charts

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart

Intraday Astrazeneca Chart

Intraday Astrazeneca Chart

Astrazeneca (AZN) Discussions and Chat

Astrazeneca Forums and Chat

Date Time Title Posts
12/7/201908:09Alzheimer's can be caught .... It's a transmissible disease95
03/7/201921:52AstraZeneca2,188
01/5/201919:48why the fall-
13/2/201911:48AstraZeneca Full Year Results on Thursday-
15/10/201818:31*** AstraZeneca *** 360

Add a New Thread

Astrazeneca (AZN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Astrazeneca trades in real-time

Astrazeneca (AZN) Top Chat Posts

DateSubject
21/7/2019
09:20
Astrazeneca Daily Update: Astrazeneca Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 6,402p.
Astrazeneca Plc has a 4 week average price of 6,291p and a 12 week average price of 5,626p.
The 1 year high share price is 6,634p while the 1 year low share price is currently 5,312p.
There are currently 1,311,776,898 shares in issue and the average daily traded volume is 1,677,635 shares. The market capitalisation of Astrazeneca Plc is £83,822,543,782.20.
18/6/2019
13:01
bluemango: Meanwhile, share price only needs to put on just over 2% more and it will be surpassing all time high of £65.40. Good trials results and new approvals keep flowing through and should eventually be translated into earnings and dividend growth.
18/7/2018
12:01
bountyhunter: http://uk.advfn.com/stock-market/london/astrazeneca-AZN/share-news/AstraZeneca-Increases-Drug-Stockpile-in-Preparatio/77885692 that's one way to reduce any potential initial WTO tariffs/bottlenecks!
08/10/2017
12:51
cool druid: [...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance | Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance Read more: http://www.thisismoney.co.uk/money/investing/article-4955948/Advanced-Oncotherapy-enjoys-64-share-price-boost.html#ixzz4uoWb91d9 A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment
30/7/2017
19:12
nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend."
28/7/2017
15:10
minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh?
27/7/2017
10:46
minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675.
27/7/2017
10:10
steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend.
27/1/2017
09:02
steeplejack: Goldmans issued a sell note on the 24 Jan with a £39 share price target.Thats probably still washing through.
20/1/2017
17:26
philanderer: "Is Neil Woodford a fool to continue pumping money into Capita plc and AstraZeneca plc? 'Patience' AstraZeneca is Woodford's largest holding and an example of just how long he's prepared to be patient with a company he views as intrinsically undervalued. Earnings at the pharma group have suffered as a result of expiring patents on some of its top sellers and no improvement is expected to the bottom line until 2018. However, the company has maintained its dividend through this difficult period and offers a 5% yield at a current share price of around 4,400p. The dividend is forecast to start rising with the resumption of earnings growth in 2018 as a result of Astra's reinvigorated drugs pipeline. HTTP://money.aol.co.uk/2017/01/20/is-neil-woodford-a-fool-to-continue-pumping-money-into-capita-pl/
02/5/2014
08:43
harvester: Share price below indicative offer since not all cash offer and risk of pfizer share price weakening as well as risk of the deal failing . AZN share price closed last night at 4851 up 151 based on suspicious after hours trades . At normal market close the share price was 4676.5 . Big money at stake. Hence bound to be some insider trading going on .
Astrazeneca share price data is direct from the London Stock Exchange
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190721 10:42:28